Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

British Journal of Cancer

Volumn 89, Issue 7, 2003, Pages 1334-1344

  Hori, K ^a   Saito, S ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Combretastatin A 4; Haemolysis; Interstitial fluid pressure; Tumour blood flow; Tumour vessel

Indexed keywords

COMBRETASTATIN A4; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; EUROPE; HEMOLYSIS; HEMOSTASIS; KIDNEY TUMOR; LUNG CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; SARCOMA; THROMBOSIS; TISSUE PRESSURE; TUMOR BLOOD FLOW; UNITED STATES;

ANIMALS; ARTERIOLES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; LUNG NEOPLASMS; MALE; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR; NEOPLASM TRANSPLANTATION; RATS; SARCOMA, YOSHIDA; SERINE; TUMOR CELLS, CULTURED; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0242329757     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601261     Document Type: Article

References (47)

1. Aukland K, Bower BF, Berliner RW (1964) Measurement of local blood flow with hydrogen gas. Circ Res 14: 164-187
2. 4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761-1767
3. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, Longo DL (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 53: 2204-2207
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834
5. Dowlati A, Robertson K, Cooney M, Petrons WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
6. 4 An rat gliomas. Cancer Lett 178: 209-217
7. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327
8. Gullino PM, Clark SH, Grantham PH (1964) The interstitial fluid of solid tumor. Cancer Res 24: 780-797
9. Gullino PM, Grantham FH (1961) Studies on the exchange of fluids between host and tumor. I. A method for growing 'tissue-isolated' tumors in laboratory animals. J Natl Cancer Inst 27: 679-693
10. Hatanaka T, Fujita K, Ohsumi K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Akiyama Y, Tsuji T (1998) Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg Med Chem Lett 8: 3371-3374
11. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90: 1026-1038
12. Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86: 1604-1614
13. Hori K, Saito S, Sato Y, Kubota K (2001) Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 7: 26-33
14. Hori K, Suzuki M, Abe I, Saito S (1986) Increased tumor tissue pressure in association with the growth of rat tumors. Jpn J Cancer Res 77: 65-73
15. Hori K, Suzuki M, Abe I, Saito S, Sato H (1981) New technique for measurements of microvascular pressure in normal and tumor vessels of rats. Invas Metast 1: 248-260
16. Hori K, Suzuki M, Tanda S, Saito S (1990) In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81: 279-288
17. Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang Q-H (1991) Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn J Cancer Res 82: 1309-1316
18. Hori K, Zhang Q-H, Li H-C, Saito S (1995) Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow. Br J Cancer 71: 1163-1168
19. Hori K, Zhang Q-H, Li H-C, Saito S, Sato Y (1996) Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int J Cancer 65: 360-364
20. Hori K, Zhang Q-H, Saito S, Tanda S, Li H-C, Suzuki M (1993) Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res 53: 5528-5534
21. Horsman MR, Ehrnrooth E, Ladekari M, Overgaard J (1998) The effect of combretastatin A-4 disodium phosphate in a C3 H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42: 895-898
22. Jain RK (1987) Transport of molecules across tumor vasculature. Cancer Metast. Rev 6: 559-593
23. Konerding MA, Steinberg F, Streffer C (1989) The vasculature of xenotransplanted human melanomas and sarcomas on nude mice. II. Scanning and transmission electron microscopic studies. Acta Anat 136: 27-33
24. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J, van Oosterom A, Lambin P (2000) Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36: 1833-1843
25. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE (2001) Combretastatin A-4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7: 1052-1060
26. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000
27. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T (1999a) A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 90: 1016-1025
28. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y (1999b) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90: 1387-1395
29. Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61: 711-716
30. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T (1998) Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 41: 3022-3032
31. Papadimitriou JM, Woods AE (1975) Structural and functional characteristics of the microcirculation in neoplasms. J Pathol 116: 65-72
32. Paskins-Hurlburt AJ, Hollenberg NK, Abrams HL (1982) Tumor perfusion in relation to the rapid growth phase and necrosis: studies on the Walker carcinoma in the rat testicle. Microvasc Res 24: 15-24
33. Peterson H-I (1979) Tumor blood flow compared with normal tissue blood flow. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors, Peterson H-I (ed) pp 103-114 Boca Raton, FL: CRC Press
34. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209-211
35. Pettit GR, Temple Jr C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322 Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299-309
36. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695-6698
37. Scholander PF, Hargens AR, Miller SL (1968) Negative pressure in the interstitial fluid of animals. Science 161: 321-328
38. Simionescu M, Simionescu N (1984) Ultrastructure of the microvascular wall: functional correlations. In Handbook of Physiology Section 2: Cardiovascular System, Geiger SV (ed) pp 41-101 Baltimore: American Physiology Society
39. Strahler AN (1957) Quantitative analysis of watershed geomorphology. Trans Am Geophys Union 38: 913-920
40. Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38
41. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634
42. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422
43. Wiedeman MP (1984) Architecture. In Handbook of Physiology Section 2: Cardiovascular System, Geiger SV (ed) pp 11-40. Baltimore: American Physiology Society
44. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L (1982) Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159-164
45. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10
46. Yamaura H, Sato H (1974) Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 53: 1229-1240
47. Zhao S, Moore JV, Waller ML, McGown AT, Hadfield JA, Pettit GR, Hastings DL (1999) Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med 26: 231-238